Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model

Current Oncology

Volumn 14, Issue 5, 2007, Pages 167-172

  Hopkins, M Laura ^a   Coyle, D ^a   Le, T ^a   Fung Kee Fung, M ^a   Wells, G ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

CA 125; Decision analysis; preferences

Indexed keywords

EID: 42649102723     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.144     Document Type: Article

References (29)

1. Vergote IB, Børmer OP, Abeler VM. Elevation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 1987;157:88–92.
2. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC Jr. CA-125 for the monitoring of ovarian carcinoma during primary treatment. Obstet Gynecol 1987;69:223–7.
3. Sevelda P, Schemper M, Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1989;161:1213–16.
4. Podczaski E, Whitney C, Manetta A, et al. Use of CA 125 to monitor patients with ovarian epithelial carcinomas. Gynecol Oncol 1989;33:193–7.
5. Svelda P, Wagner G. Diagnosis of the recurrence of epithelial ovarian cancer with the tumor marker CA 125 [German]. Wien Klin Wochenschr 1987;99:768–70.
6. Niloff JM, Bast RC Jr, Schaetzl EM, Knapp RC. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985;151:981–6.
7. Markman M. Follow-up of the asymptomatic patient with ovarian cancer. Gynecol Oncol 1994;55(Pt 2):S134–7.
8. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26–35.
9. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340–8.
10. Gaducci A, Sartori E, Zola P. Serum CA-125 in the early diagnosis of recurrent epithelial ovarian cancer: a CFT study. Oncol Rep 1996;3:301–3.
11. Rustin GJ, Bast RC Jr, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004;10:3919–26.
12. Gore M. The treatment of relapsed epithelial ovarian cancer. In: Perry MC, ed. American Society of Clinical Oncology Edu-cational Book. Alexandria, VA: American Society of Clinical Oncology; 2001: 468–76.
13. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7:361–4.
14. Markman M. Resetting the CA-125 range for a complete re-sponse to chemotherapy: why? Gynecol Oncol 1994;53:281–2.
15. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–con-trol studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184–203.
16. Canadian Cancer Society, the National Cancer Institute of Canada, and Statistics Canada. Canadian Cancer Statistics 2003. Ottawa: Canadian Cancer Society; 2003.
17. Bush JW. Relative preference versus relative frequencies in health-related quality of life evaluations. In: Wenger NK, edi-tor. Assessment of Quality of Life in Clinical Trials of Cardio-vascular Therapies. New York: Le Jacq Pub; 1984: 118–39.
18. Torrance GW. Social preferences for health states: an empiri-cal evaluation of three measurement techniques. Socioecon Plann Sci 1976;10:129–36.
19. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1172–7.
20. The EuroQOL Group. EuroQOL—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199–208.
21. Ozols RF. Update on the management of ovarian cancer. Cancer J 2002;8:S22–30.
22. Canada, Statistics Canada, Health Statistics Division. Life Tables, Canada and Provinces, 1990–92. Standardized Data on Death Rates According to Age and Sex. Ottawa: Statistics Canada; 1995.
23. Ozols RF, Schwartz PE, Eifel PJ, et al. Ovarian cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins; 2001: 1597–632.
24. Eltabbakh GH, Awtrey CS. Current treatment for ovarian can-cer. Expert Opin Pharmacother 2001;2:109–24.
25. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883–7.
26. DeLorey C. Women at midlife: women’s perceptions, physi-cians’ perceptions. J Women Aging 1989;1:57–69.
27. Boyd NF, Sutherland HJ, Heasman KZ, Tritchler DL, Cummings BJ. Whose utilities for decision analysis? Med Decis Making 1990;10:58–67.
28. Llewellyn–Thomas HA, Sutherland HJ, Thiel EC. Do patients’ evaluations of a future health state change when they actually enter that state? Med Care 1993;31:1002–12.
29. Calhoun EA, Fishman DA, Lurain JR, Welshman EE, Bennett CL. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk popula-tion, general population, and physicians. Gynecol Oncol 2004; 93:164–9.